Hexadecylamine
CAS 143-27-1
Hexadecylamine (CAS 143-27-1) is a Phase 2 pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 11220.2 nM | 1 | - |
| - | MIC | 130000 nM | 1 | - |
| - | Potency | 15848.9 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Hexadecylamine used for in pharmaceutical contexts?
Hexadecylamine (CAS 143-27-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Hexadecylamine?
No adverse-event association or SIDER side-effect rows are rendered for Hexadecylamine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Hexadecylamine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for PALMITAMINE with EU status "restricted".
What clinical phase is Hexadecylamine in?
Hexadecylamine is rendered with ChEMBL max phase 2.